BioTelemetry (NASDAQ:BEAT) will issue its quarterly earnings data after the market closes on Thursday, February 21st. Analysts expect the company to announce earnings of $0.41 per share for the quarter.
NASDAQ:BEAT opened at $76.30 on Thursday. The company has a current ratio of 2.68, a quick ratio of 2.50 and a debt-to-equity ratio of 0.66. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of 78.66, a price-to-earnings-growth ratio of 4.16 and a beta of 1.75. BioTelemetry has a 52 week low of $29.85 and a 52 week high of $80.92.
BEAT has been the topic of a number of recent analyst reports. Raymond James decreased their price target on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Wednesday, October 31st. BidaskClub raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Friday, January 11th. Sidoti set a $95.00 price target on BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a report on Tuesday, February 5th. Finally, ValuEngine raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $70.57.
In other news, VP Heather C. Getz sold 8,236 shares of BioTelemetry stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $70.01, for a total value of $576,602.36. Following the sale, the vice president now directly owns 88,797 shares of the company’s stock, valued at $6,216,677.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Heather C. Getz sold 64,989 shares of BioTelemetry stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $70.09, for a total value of $4,555,079.01. Following the completion of the sale, the chief financial officer now directly owns 119,085 shares in the company, valued at $8,346,667.65. The disclosure for this sale can be found here. Insiders sold 177,198 shares of company stock worth $12,419,736 over the last ninety days. Insiders own 8.30% of the company’s stock.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
See Also: Depreciation
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.